Topoisomerase inhibitors as therapeutic weapons

Expert Opinion on Therapeutic Patents

Volumn 17, Issue 5, 2007, Pages 521-532

  Cortés, Felipe ^a   Pastor, Nuria ^a   Mateos, Santiago ^a   Domínguez, Inmaculada ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Antibacteria; Anticancer chemotherapy; Antifungi; Antiprotozoa; DNA topoisomerases; Topoisomerase inhibitors

Indexed keywords

1,2 BIS(3,5 DIOXOPIPERAZIN 1 YL)ETHANE; 4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; ACLARUBICIN; AMSACRINE; ANTHRACYCLINE DERIVATIVE; ANTHRAQUINONE; BERBERINE; CAMPTOTHECIN; DAUNORUBICIN; DIMINAZENE ACETURATE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EDOTECARIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; GIMATECAN; HOE 33342; IRINOTECAN; LUTEOLIN; MERBARONE; MITOXANTRONE; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAZOXANE; SURAMIN; TENIPOSIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XR 5000;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROTOZOAL ACTIVITY; ASPERGILLUS NIGER; BACTERIAL INFECTION; BREAST CANCER; CANCER CHEMOTHERAPY; CANDIDA ALBICANS; CELL SURVIVAL; CLINICAL TRIAL; DNA CLEAVAGE; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG EFFICACY; DRUG PENETRATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; KAPOSI SARCOMA; LEISHMANIASIS; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; OVARY CANCER; PROTOZOAL INFECTION; REVIEW; TUBERCULOSIS;

EID: 34248374799     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.17.5.521     Document Type: Review

References (60)

1. GILES GI, SHARMA RP: Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med. Chem. (2005) 1(4):383-394.
2. BALAÑA-FOUCE R, REDONDO CM, PÉREZ-PERTEJO Y, DÍAZ-GONZÁLEZ R, REGUERA RM: Targeting atypical trypanosomatid DNA topoisomerase I. Drug Discov. Today (2006) 11(15,16):733-740.
3. REGUERA RM, REDONDO CM, GUTIÉRREZ DE PRADO R, PÉREZ-PERTEJO Y, BALAÑA-FOUCE R: DNA topoisomerase I from parasitic protozoa: a potential target for chemotherapy. Biochim. Biophys. Acta. (2006) 1759:117-131.
4. PASTOR N, CORTÉS F: Bufalin influences the repair of X-ray-induced DNA breaks in Chinese hamster cells. DNA Repair (2003) 2:1353-1360.
5. HAYASHI S, HATASHITA M, MATSUMOTO H, SHIOURA H, KITAI R, KANO E: Enhancement of radiosensitivity by topoisomerase II inhibitor, amrubicin and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction. Int. J. Mol. Med. (2006) 18(5):909-915.
6. CORTÉS F, PASTOR N: Induction of endoreduplication by topoisomerase II catalytic inhibitors. Mutagenesis (2003)18:105-112.
7. CORTÉS F, PASTOR N, MATEOS S, DOMÍNGUEZ I: Roles of DNA topoisomerases in chromosome segregation and mitosis. Mútat. Res. (2003) 543:59-66.
8. SULLIVAN DM, LATHAM MD, ROSS WE: Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse and Chinese hamster ovary cells. Cancer Res. (1987) 47:3973-3979.
9. LIU LF: DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. (1989) 58:351-375.
10. BURDEN DA, OSHEROFF N: Mechanisln of action of eukaryotic topoisnmerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta. (1998) 1400:139-154.
11. WANG JC: DNA topoisomerases. Annu. Rev. Biochem. (1996) 65:635-692.
12. SANDER M, HSIEH T, UDVARDY A, SCHEDL P: Sequence dependence of Drosophila topoisomerase II in plasmid relaxation and DNA binding. J. Mol. Biol. (1987) 194:219-229.
13. SPITZNER JR, MULLER MT: A consensus sequence for cleavage by vertebrate DNA topoisomcrase II. Nucleic Acids Res. (1988) 16:5533-5556.
14. LEE MP, SANDER M, HSIEH T: Nuclease protection by Drosophila DNA topoisomerase II. Enzylne/DNA contacts at the strong topoisomerase II cleavage sites. J. Biol. Chem. (1989) 264:21779-21787.
15. POMMIER Y, CAPRANICO G, ORR A, KOHN KW: Distribution of topoisonterase II cleavage sites in simian virus 40 DNA and the effects of drugs. J. Mol. Biol. (1991) 222:909-924.
16. ADAMS DJ: The impact of tumor physiology on camptothecin-based drug development. Curr. Med. Chem. Anticancer Agents (2005) 5:1-13.
17. SRIRAM D, YOGEESWARI P, THIRUMURUGAN R, BAL TR: Camptothecin and its analogues: a review on their chemotherapeutic potential. Nat. Prod. Res. (2005) 19(4):393-412.
18. THOMAS CJ, RAHIER NJ, HECHT SM: Camptothecin: current perspectives. Bioorg. Med. Chem. (2004) 12:1585-1604.
19. POMMIER Y: Topoisomerase 1 inhibitors: camptothecins and beyond. Nat. Rev. Cancer (2006) 6(10):789-802.
20. WAKELEE HA, SIKIC BI: Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors. Clin. Lung Cancer (2005) 7(Suppl. 1):S6-S12.
21. SAIF MW, DIASIO RB: Edotecarin: a novel topoisomerase I inhibitor. Clin. Colorectal Cancer (2005) 5(1):27-36.
22. CHEN AY, LIU LF: DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. (1994) 34:191-218.
23. FROELICH-AMMON SJ, OSHEROFF N: Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem. (1995) 270:21429-21432.
24. BINASCHI M, ZUNINO F, CAPRANICO G: Mechanism of action of DNA topoisomerase inhibitors. Stem Cells (1995) 13:369-379.
25. NITISS JL, BECK WT: Antitopoisomerase drug action and resistance. Eur. J. Cancer (1996) 32A:958-966.
26. ANDOH T, ISHIDA R: Catalytic inhibitors of DNA topoisomerase II. Biochim. Biophys. Acta. (1998) 1400:155-171.
27. LARSEN AK, ESCARGUEIL AE, SKLADANOWSKI A: Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol. Ther. (2003) 99:167-181.
28. CHEN M, BECK WT: Weniposide-resistant CEM cells, which express mutant DNA topoisomerase IIα, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res. (1993) 53(24):5946-5953.
29. BOJANOWSKI K, LELIEVRE S, MARKOVITS J, COUPREE J, JACQUEMIN-SABLON A, LARSEN AK: Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc. Natl. Acad. Sci. USA. (1992) 89:3025-3029.
30. JENSEN PB, SØRENSON BS, DEMANT EJ et al.: Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)-methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res. (1990) 50:3311-3316.
31. DRAKE FH, HOFMANN GA, MONG SM et al.: In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res. (1989) 49:2578-2583.
32. BORITZKI TJ, WOLFARD TS, BESSERER JA, JACKSON RC, FRY DW: Inhibition to type II topoisomerase by fostriecin. Biochem. Pharmacol. (1998) 37:4063-4068.
33. UTSUMI H, SHIBUYA ML, KOSAKA T, BUDDENBAUM WE, ELKIND MM: Abrogation by novobiocin of cytotoxicity due to the topoisomerase II inhibitor amsacrine in Chinese hamster cells. Cancer Res. (1990) 50:2577-2581.
34. JENSEN LH, NITISS KC, ROSE A et al.: A novel mechanism of cell killing by antitopoisomerase II bis-dioxopiperazines. J. Biol. Chem. (2000) 275:2137-2146.
35. HUANG KC, GAO H, YAMASAKI EF et al.: Topoisomerase II poisoning by ICRF-193. J. Biol. Chem. (2001) 276:44488-44494.
36. HAJJI N, PASTOR N, MATEOS S, DOMINGUEZ I, CORTÉS F: DNA strand breaks induced by the antitopoisomerase II bis-dioxopiperazine ICRF-193. Mutat. Res. (2003) 530:35-46.
37. CORTÉS F, PIÑERO J: Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured CHO cells. Cancer Chemother. Pharmacol. (1994) 34:411-415.
38. DENNY WA, BAGULEY BC: Dual topoisomerase I/II inhibitors in cancer therapy. Curr. Top. Med. Chem. (2003) 3(3):339-353.
39. DITTRICH C, COUDERT B, PAZ-ARES L et al.: Phase II study of XR 5000(DACA), an inhibitor of topoisomerase I and II, administered as a 120 h infusion in patients with non-small cell lung cancer. Eur. J. Cancer (2003) 39(3):330-334.
40. WASSERMANN K, MARKOVITS J, JAXEL C, CAPRANICO G, KOHN KW, POMMIER Y: Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol. Pharmacol. (1990) 38:38-45.
41. ETIÉVANT C, KRUCZYNSKI A, BARRET JM et al.: F11782, a dual inhibitor of topoisomerase I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103. Cancer Chemother. Pharmacol. (2000) 46:102-113.
42. HAJJI N, MATEOS S, PASTOR N, DOMÍNGUEZ I, CORTÉS F: Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. Mutat. Res. (2005) 583:26-35.
43. WANG B, PERCHELLET EM, WANG Y, TAMURA M, HUA DH, PERCHELLET JP: Antitumor triptycene bisquinones: a novel synthetic class of dual inhibitors of DNA topoisomerase I and II activities. Anticancer Drugs (2003) 14(7):503-514.
44. SISSI C, PALUMBO M: The quinnlone family: from antibacterial to anticancer agents. Curr. Med. Chem. Anticancer Agents (2003) 3(6):439-450.
45. HEATON VJ, AMBLERJE, FISHER LM: Potent antipneunmococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob. Agents Chemother. (2000) 44(11):3112-3117.
46. JACOBS MR: Fluoroquinolones as chemotherapeutics against mycobacterial infections. Curr. Pharm. Des. (2004) 10(26):3213-3220.
47. WILES JA, HASHIMOTO A, THANASSI JA et al.: Isothiazolopyridones: synthesis, structure, and biological activity of a new class of antibacterial agents. J. Med. Chem. (2006) 49(1):39-42.
48. MANI N, GROSS CH, PARSONS JD et al.: In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class. Antimicrob. Agents Chemother. (2006) 50(4):1228-1237.
49. CHENG B, SHUKLA S, VASUNILASHORN S, MUKHOPADHYAY S, TSE-DINH YC: Bacterial cell killing mediated by topoisomerase I DNA cleavage activity. J. Biol. Chem. (2005) 280(46):38489-38495.
50. VILLA H, OTERO MARCOS AR, REGUERA RM et al.: A nowel active DNA topoisomerase I in Leishmania donovani. J. Biol. Chem. (2003) 278:3521-3526.
51. PROULX ME, DESORMEAUX A, MARQUIS JE OLIVIER M, BERG ERON MG: Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin. Antimicrob. Agents Chemother. (2001) 45(9):2623-2627.
52. MITTRA B, SAHA A, CHOWDHURY AR et al.: Luteolin, an abundant dietary component is a potent antileishmanial agent that acts by inducing topoisomerase II-mediated kinetoplast DNA cleavage leading to apoptosis. Mol. Med. (2000) 6(6):527-541.
53. SUNDRIYAL S, SHARMA RK, JAIN R: Current advances in antifungal targets mad drug development. Curr. Med. Chem. (2006) 13(11):1321-1335.
54. SHEN LL, BARANOWSKI J, FOSTEL J, MONTGOMERY DA, LARTEY PA: DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs. Antimicrob. Agents Chemother. (1992) 36(12):2778-2784.
55. FOSTEL J, MONTGOMERY D: Identification of the aminocatechol A-3253 as an in vitro poison of DNA topoisomerase I from Candida albicans. Antimicrob. Agents Chemother. (1995) 39(3):586-592.
56. GOLDMAN GH, YU C, WU HY, SANDERS MM, LA VOIE EJ, LIU LF: Differential poisoning of human and Aspergillus nidulans DNA topoisomerase I by bi- and terbenzimidazoles. Biochemistry (1997) 36(21):6488-6494.
57. KHAN SI, NIMROD AC, MEHRPOOYA M, NITISS JL, WALKER LA, CLARK AM: Antifungal activity of eupolauridine and its action on DNA topoisomerases. Antimicrob. Agents Chemother. (2002) 46(6):1785-1792.
58. MANOCHAKIA RN, MILLER KC, CHANAN-KHAN AA: Bortezomib in combination with pegylated liposomal Doxorubicin for the treaunent of multiple myeloma. Clin. Lymphoma Myeloma. (2007) 7(4):266-271.
59. AMINOVA LR, CHAVEZ JC, LEE J et al.: Prosurvival and prodeath effects of hypoxia-inducible factor-1α stabilization in a murine hippocampal cell line. J. Biol. Chem. (2005) 280(5):3996-4003.
60. RAPISARDA A, URANCHIMEG B, SORDET O, POMMIER Y, SHOEMAKER R H, MELILLO G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1. Mechanism and therapeutic implications. Cancer Res. (2004) 64:1475-1482.